A Phase 2 interventional study of risankizumab and placebo for risankizumab in Arthritis, Psoriatic, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-30.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.
Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2016, is one of 5 in phase 2, and was the 16th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Czechia and 3 more countries
Ages 18+
AbbVie · Sites in Argentina, Austria, Belgium and 12 more countries
Ages 18–75
AbbVie · Sites in United States, Australia, Canada and 6 more countries
Ages 5–17
AbbVie · Sites in United States
Women only
By country, each count listing its studies:
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 246 across the 11 interventional studies, 474 across the 22 observational. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Arthritis, Psoriatic by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066/ABBV-066/risankizumab in adult patients with psoriatic arthritis in order to select doses for further clinical trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
Drug: placebo for risankizumab
Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
Drug: risankizumab
Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
Drug: risankizumab
Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
Drug: risankizumab
Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.
Drug: risankizumab
Risankizumab administered by SC injection
Also known as: BI 655066, ABBV-066, SKYRIZI
Placebo for risankizumab administered by SC injection
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16
Response defined by ACR20 criteria (improvement from baseline) at Week 16: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * Health Assessment Questionnaire Disability Index (HAQ-DI) * Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 16
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 16
Response defined by ACR50 criteria (improvement from baseline) at Week 16: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * HAQ-DI * Acute phase reactant value (C-reactive protein). NRI was used for missing data.
Time frame: Week 16
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 16
Response defined by ACR70 criteria (improvement from baseline) at Week 16: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * HAQ-DI * Acute phase reactant value (C-reactive protein). NRI was used for missing data.
Time frame: Week 16
Tender Joint Count (TJC68): Change From Baseline to Week 16
Sixty-eight joints were assessed and classified as either tender (1) or not tender (0). A negative change represents a decrease in the number of tender joints.
Time frame: Baseline, Week 16
Swollen Joint Count (SJC): Change From Baseline to Week 16
Sixty-six joints were assessed and classified as either swollen (1) or not swollen (0). A negative change represents a decrease in the number of tender joints.
Time frame: Baseline, Week 16
Health Assessment Questionnaire Disability Index (HAQ-DI) Score: Change From Baseline to Week 16
The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. A negative change from Baseline indicates improvement.
Time frame: Baseline, Week 16
Short Form-36 Health Status Survey (SF-36) Physical Component: Change From Baseline to Week 16
The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.
Time frame: Baseline, Week 16
SF-36 Mental Component: Change From Baseline to Week 16
The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.
Time frame: Baseline, Week 16
Dactylitis Count: Change From Baseline to Week 16 in Participants With Dactylitis at Baseline
The number of fingers and toes with dactylitis (ranging from 0 to 20). A negative change represents a decrease in the number of fingers and toes affected by dactylitis.
Time frame: Baseline, Week 16
Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Change From Baseline to Week 16 in Participants With Enthesitis at Baseline
Assessment of enthesitis was performed in the following 16 domains: left and right (L/R) medial epicondyle; L/R lateral epicondyle; L/R supraspinatus insertion into the greater tuberosity of humerus; L/R greater trochanter; L/R quadriceps insertion into superior border of patella; L/R patellar ligament insertion into inferior pole of patella or tibial tubercle; L/R Achilles tendon insertion into calcaneum; L/R plantar fascia insertion into calcaneum. Tenderness at each site was classified as either absent (0) or present (1) to yield total SPARCC scores ranging from 0 (0 sites with tenderness) to 16 (16 sites with tenderness). A negative change from Baseline indicates improvement.
Time frame: Baseline, Week 16
Modified Nail Psoriasis Severity Index (mNAPSI): Change From Baseline to Week 16
mNAPSI grades each fingernail for onycholysis (separation of the nail plate from the nail bed) and oil-drop (salmon patch) dyschromia (reddish-brown discoloration under the nail plate) on a scale of 0 (none present) to 3 (\>30% of the nail); pitting (small, sharply defined depressions in the nail surface) on a scale of 0 (0 pits present) to 3 (\>50 pits present); nail plate crumbling on a scale of 0 (no crumbling) to 3 (\>50% of nail has crumbling); and presence (1) or absence (0) of leukonychia (white spots), splinter hemorrhages, nail bed hyperkeratosis, and red spots in the lunula. mNAPSI is calculated as the sum of all the components for all of the participants fingernails, for a minimal - maximal total score of 0 to 130. A negative change from Baseline indicates improvement.
Time frame: Baseline, Week 16
Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. The percentage of participants achieving PASI90 at Week 16 are provided. NRI was used for missing data.
Time frame: Week 16
| Milestone | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 |
|---|---|---|---|---|---|
| Started | 42 | 42 | 42 | 39 | 20 |
| Completed | 41 | 38 | 39 | 37 | 18 |
| Not completed | 1 | 4 | 3 | 2 | 2 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Subject withdrawal | 0 | 2 | 2 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 |
Response defined by ACR20 criteria (improvement from baseline) at Week 16: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * Health Assessment Questionnaire Disability Index (HAQ-DI) * Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16 | 35.7 (23.5 to 49.5) | 57.1 (43.3 to 70.2) | 61.9 (48.0 to 74.4) | 59.0 (44.6 to 72.3) | 65.0 (44.2 to 82.3) | 59.5 (50.0 to 68.6) | 60.5 (50.8 to 69.6) |
Response defined by ACR50 criteria (improvement from baseline) at Week 16: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * HAQ-DI * Acute phase reactant value (C-reactive protein). NRI was used for missing data.
| percentage of participants | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 16 | 11.9 (4.8 to 23.4) | 23.8 (13.5 to 37.0) | 23.8 (13.5 to 37.0) | 38.5 (25.4 to 52.9) | 25.0 (10.4 to 45.6) | 23.8 (16.4 to 32.7) | 30.9 (22.5 to 40.4) |
Response defined by ACR70 criteria (improvement from baseline) at Week 16: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * HAQ-DI * Acute phase reactant value (C-reactive protein). NRI was used for missing data.
| percentage of participants | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 16 | 0.0 (0.0 to 6.9) | 14.3 (6.4 to 26.3) | 7.1 (2.0 to 17.4) | 25.6 (14.6 to 39.6) | 15.0 (4.2 to 34.4) | 10.7 (5.7 to 18.0) | 16.0 (9.8 to 24.3) |
Sixty-eight joints were assessed and classified as either tender (1) or not tender (0). A negative change represents a decrease in the number of tender joints.
| tender joints | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Tender Joint Count (TJC68): Change From Baseline to Week 16 | -7.9 (-10.6 to -5.2) | -7.8 (-10.6 to -5.1) | -9.6 (-12.4 to -6.9) | -10.4 (-13.2 to -7.5) | -10.8 (-14.9 to -6.8) | -8.6 (-10.5 to -6.6) | -9.9 (-11.8 to -8.0) |
Sixty-six joints were assessed and classified as either swollen (1) or not swollen (0). A negative change represents a decrease in the number of tender joints.
| swollen joints | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Swollen Joint Count (SJC): Change From Baseline to Week 16 | -7.1 (-8.5 to -5.7) | -6.8 (-8.3 to -5.4) | -7.8 (-9.3 to -6.4) | -8.3 (-9.7 to -6.8) | -7.8 (-9.9 to -5.7) | -7.3 (-8.5 to -6.2) | -8.3 (-9.4 to -7.2) |
The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. A negative change from Baseline indicates improvement.
| units on a scale | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Health Assessment Questionnaire Disability Index (HAQ-DI) Score: Change From Baseline to Week 16 | -0.089 (-0.204 to 0.026) | -0.182 (-0.299 to -0.065) | -0.163 (-0.280 to -0.047) | -0.245 (-0.365 to -0.126) | -0.147 (-0.317 to 0.023) | -0.184 (-0.270 to -0.099) | -0.206 (-0.291 to -0.120) |
The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.
| units on a scale | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Short Form-36 Health Status Survey (SF-36) Physical Component: Change From Baseline to Week 16 | 1.93 (0.17 to 3.70) | 3.87 (2.03 to 5.71) | 3.50 (1.72 to 5.27) | 3.10 (1.27 to 4.93) | 7.42 (4.81 to 10.03) | 3.80 (2.52 to 5.08) | 3.32 (2.03 to 4.62) |
The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.
| units on a scale | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| SF-36 Mental Component: Change From Baseline to Week 16 | 0.48 (-1.74 to 2.69) | -0.36 (-2.68 to 1.96) | 2.26 (0.03 to 4.49) | 2.84 (0.54 to 5.14) | -1.08 (-4.35 to 2.19) | 1.31 (-0.38 to 3.00) | 2.29 (0.59 to 3.99) |
The number of fingers and toes with dactylitis (ranging from 0 to 20). A negative change represents a decrease in the number of fingers and toes affected by dactylitis.
| fingers and toes with dactylitis | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Dactylitis Count: Change From Baseline to Week 16 in Participants With Dactylitis at Baseline | -2.6 (-3.9 to -1.4) | -1.1 (-2.2 to 0.1) | -1.9 (-3.0 to -0.8) | -2.9 (-4.1 to -1.7) | -3.5 (-5.2 to -1.8) | -1.5 (-2.4 to -0.6) | -2.4 (-3.0 to -1.9) |
Assessment of enthesitis was performed in the following 16 domains: left and right (L/R) medial epicondyle; L/R lateral epicondyle; L/R supraspinatus insertion into the greater tuberosity of humerus; L/R greater trochanter; L/R quadriceps insertion into superior border of patella; L/R patellar ligament insertion into inferior pole of patella or tibial tubercle; L/R Achilles tendon insertion into calcaneum; L/R plantar fascia insertion into calcaneum. Tenderness at each site was classified as either absent (0) or present (1) to yield total SPARCC scores ranging from 0 (0 sites with tenderness) to 16 (16 sites with tenderness). A negative change from Baseline indicates improvement.
| units on a scale | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Change From Baseline to Week 16 in Participants With Enthesitis at Baseline | -1.1 (-2.1 to -0.2) | -1.4 (-2.3 to -0.5) | -2.4 (-3.3 to -1.4) | -1.8 (-2.7 to -0.8) | -3.7 (-5.1 to -2.3) | -1.7 (-2.4 to -1.0) | -2.1 (-2.7 to -1.4) |
mNAPSI grades each fingernail for onycholysis (separation of the nail plate from the nail bed) and oil-drop (salmon patch) dyschromia (reddish-brown discoloration under the nail plate) on a scale of 0 (none present) to 3 (\>30% of the nail); pitting (small, sharply defined depressions in the nail surface) on a scale of 0 (0 pits present) to 3 (\>50 pits present); nail plate crumbling on a scale of 0 (no crumbling) to 3 (\>50% of nail has crumbling); and presence (1) or absence (0) of leukonychia (white spots), splinter hemorrhages, nail bed hyperkeratosis, and red spots in the lunula. mNAPSI is calculated as the sum of all the components for all of the participants fingernails, for a minimal - maximal total score of 0 to 130. A negative change from Baseline indicates improvement.
| units on a scale | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Modified Nail Psoriasis Severity Index (mNAPSI): Change From Baseline to Week 16 | -5.2 (-7.4 to -3.0) | -6.7 (-9.4 to -4.1) | -5.8 (-8.2 to -3.4) | -10.7 (-13.1 to -8.3) | -6.8 (-10.6 to -3.0) | -5.5 (-7.3 to -3.8) | -8.1 (-9.9 to -6.3) |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. The percentage of participants achieving PASI90 at Week 16 are provided. NRI was used for missing data.
| percentage of participants | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 | 9.5 (1.7 to 27.1) | 58.3 (31.5 to 81.9) | 66.7 (44.6 to 84.4) | 52.2 (33.5 to 70.4) | 55.6 (25.1 to 83.1) | 63.3 (46.7 to 77.9) | 58.5 (44.5 to 71.6) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 15 weeks after the last dose of study drug (up to 31 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/42 (0%) | 2/42 (4.8%) | 25/42 (59.5%) |
| Risankizumab 150 mg Every 4 Weeks | 0/42 (0%) | 3/42 (7.1%) | 16/42 (38.1%) |
| Risankizumab 150 mg Weeks 0, 4, and 16 | 0/42 (0%) | 0/42 (0%) | 13/42 (31%) |
| Risankizumab 150 mg Weeks 0 and 12 | 0/39 (0%) | 2/39 (5.1%) | 19/39 (48.7%) |
| Risankizumab 75 mg Week 0 | 0/20 (0%) | 3/20 (15%) | 13/20 (65%) |
| Event | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 |
|---|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| Cardiac failure congestiveCardiac disorders | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| Coronary artery occlusionCardiac disorders | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| Abdominal pain upperGastrointestinal disorders | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| GastroenteritisInfections and infestations | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| InfluenzaInfections and infestations | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| Pyelonephritis acuteInfections and infestations | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| SepsisInfections and infestations | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| Urinary tract infectionInfections and infestations | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/42 | 0/42 | 0/42 | 0/39 | 1/20 |
| Event | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 |
|---|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 2/42 | 7/42 | 5/42 | 9/39 | 4/20 |
| Upper respiratory tract infectionInfections and infestations | 5/42 | 2/42 | 3/42 | 2/39 | 1/20 |
| HeadacheNervous system disorders | 3/42 | 3/42 | 1/42 | 3/39 | 1/20 |
| FatigueGeneral disorders | 0/42 | 3/42 | 1/42 | 1/39 | 0/20 |
| BronchitisInfections and infestations | 3/42 | 1/42 | 1/42 | 1/39 | 1/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/42 | 0/42 | 0/42 | 0/39 | 0/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/42 | 3/42 | 1/42 | 1/39 | 0/20 |
| PsoriasisSkin and subcutaneous tissue disorders | 3/42 | 1/42 | 0/42 | 0/39 | 0/20 |
| HypertensionVascular disorders | 3/42 | 0/42 | 1/42 | 1/39 | 0/20 |
| Abdominal painGastrointestinal disorders | 1/42 | 0/42 | 1/42 | 2/39 | 0/20 |
Full Analysis Set (FAS): All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Total |
|---|---|---|---|---|---|---|
| Mean | 49.0 ± 11.16 | 51.8 ± 14.56 | 50.1 ± 12.33 | 51.6 ± 11.87 | 53.8 ± 10.98 | 51.0 ± 12.35 |
| Sex: Female, Male(Participants) | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Total |
|---|---|---|---|---|---|---|
| Female | 18 | 21 | 14 | 17 | 10 | 80 |
| Male | 24 | 21 | 28 | 22 | 10 | 105 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 1 | 0 | 0 | 3 |
| Not Hispanic or Latino | 40 | 41 | 39 | 38 | 19 | 177 |
| Unknown or Not Reported | 0 | 1 | 2 | 1 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Placebo | Risankizumab 150 mg Every 4 Weeks | Risankizumab 150 mg Weeks 0, 4, and 16 | Risankizumab 150 mg Weeks 0 and 12 | Risankizumab 75 mg Week 0 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 1 |
| Asian | 5 | 6 | 3 | 4 | 4 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 36 | 35 | 37 | 34 | 15 | 157 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 2 | 1 | 1 | 5 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in May 2017, 13 months.
Results were first posted in May 2019, 2 years after primary completion. A results delay was requested in Apr 2018.
Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab